rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We completed a preliminary clinical trial applying cantilever array sensors to demonstrate identification of a BRAF(V600E) single-point mutation using total RNA obtained from biopsies of metastatic melanoma of diverse sources (surgical material either frozen or fixated with formalin and embedded in paraffin).
|
27490749 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A vemurafenib-resistant human metastatic melanoma cell line positive for the BRAF V600E mutation was established.
|
27354627 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma.
|
27336602 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Vemurafenib (Zelboraf; Genentech, CA) is a highly effective oral chemotherapy agent for patients with metastatic melanoma who carry the BRAF V600E mutation.
|
27335285 |
2017 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Dabrafenib plus trametinib significantly prolonged progression-free survival (PFS) and overall survival (OS), improved objective response rates (ORRs) and preserved health-related quality of life (HR-QOL) to a greater extent than dabrafenib (in the double-blind COMBI-d study) and vemurafenib (in the open-label COMBI-v study) in two large, randomized, phase III studies in treatment-naïve patients with unresectable or metastatic melanoma with BRAF (V600E/K) mutation.
|
27246822 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Trametinib, a selective inhibitor of mitogen-activated protein kinase kinase 1 (MEK1) and MEK2, significantly improves progression-free survival compared with chemotherapy in patients with BRAF V600E/K mutation-positive advanced or metastatic melanoma (MM).
|
27172483 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
|
27151331 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The selective BRAF inhibitors vemurafenib and dabrafenib yield high response rates and improved overall survival in patients with BRAF V600E-mutant metastatic melanoma.
|
26857260 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Intrinsic and acquired resistance of metastatic melanoma to (V600E/K)BRAF and/or MEK inhibitors, which is often caused by activation of the PI3K/AKT survival pathway, represents a major clinical challenge.
|
26790143 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Highly Concordant Results Between Immunohistochemistry and Molecular Testing of Mutated V600E BRAF in Primary and Metastatic Melanoma.
|
26695089 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.
|
26512791 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were treated with the combination of dabrafenib and trametinib had significantly longer overall and progression-free survival than those treated with vemurafenib alone.
|
26433819 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Despite the remarkable clinical activities achieved by vemurafenib and dabrafenib in treating BRAF(V600E) metastatic melanoma, their clinical efficacy in BRAF(V600E) colorectal cancer is far less impressive.
|
26208524 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
|
26109403 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The development of targeted inhibitors, like vemurafenib, has greatly improved the clinical outcome of BRAF(V600E) metastatic melanoma.
|
26105199 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
As the detection of the BRAF V600E mutation has a direct impact on treatment decision, an accurate screening for BRAF mutations in patients with advanced or metastatic melanoma is mandatory.
|
26020488 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF kinase inhibitors have dramatically affected treatment of BRAF(V600E) (/) (K)-driven metastatic melanoma.
|
25948295 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Vemurafenib, a BRAF inhibitor, is FDA-approved for the treatment of metastatic melanoma in patients who harbor the BRAF V600E mutation.
|
25942671 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We describe a 50-year-old Hispanic woman with BRAF V600E mutant metastatic melanoma who was treated with surgery, radiation therapy, interleukin-2, and was enrolled on a BRAFi (dabrafenib) trial.
|
25839886 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To present the impact of treatments on health-related quality of life (HRQoL) from the double-blind, randomised phase III COMBI-d study that investigated the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600E/K-mutant metastatic melanoma.
|
25794603 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Researchers retrospectively reviewed medical records of all patients at our institution with surgically incurable BRAF V600E mutated stage III or limited stage IV melanoma treated with induction vemurafenib, stopped electively during ongoing response, followed by consolidative radiation therapy with or without intervening surgery to debulk nodal metastases.
|
25746037 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Studies presented or published during the European Society for Medical Oncology conference demonstrate that combining BRAF and MEK inhibitors improves progression-free and overall survival--and lowers the risk of resistance and toxicities--in patients with metastatic melanoma with BRAF V600E or V600K mutations.
|
25477091 |
2014 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study is aimed to examine challenges in the clinical detection of BRAF mutations in LN specimens with metastatic melanoma and to illustrate characteristic features of p.V600E and non-p.V600E mutations.
|
25456393 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations.
|
25399551 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A combination of dabrafenib and trametinib, as compared with dabrafenib alone, improved the rate of progression-free survival in previously untreated patients who had metastatic melanoma with BRAF V600E or V600K mutations.
|
25265492 |
2014 |